Long-term efficacy and safety of alemtuzumab in advanced primary cutaneous T-cell lymphomas (pages 720–724)
A. de Masson, P. Guitera, P. Brice, I. Moulonguet, F. Mouly, J.-D. Bouaziz, M. Battistella, I. Madelaine, J. Roux, C. Ram-Wolff, J.-M. Cayuela, H. Bachelez, A. Bensussan, L. Michel and M. Bagot
Article first published online: 12 MAR 2014 | DOI: 10.1111/bjd.12690
What's already known about this topic?
- Alemtuzumab has shown short-term efficacy in small numbers of patients with advanced primary cutaneous T-cell lymphomas.
What does this study add?
- Alemtuzumab may induce long-term remission (> 2 years) in patients with Sézary syndrome.
- Alemtuzumab is poorly effective in nontransformed mycosis fungoides and transformed CTCL.